✦ LIBER ✦

PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial

✍ Scribed by Florian Lordick; Katja Ott; Bernd-Joachim Krause; Wolfgang A Weber; Karen Becker; Hubert J Stein; Sylvie Lorenzen; Tibor Schuster; Hinrich Wieder; Ken Herrmann; Rainer Bredenkamp; Heinz Höfler; Ulrich Fink; Christian Peschel; Markus Schwaiger; Jörg R Siewert

Book ID: 117784425
Publisher: The Lancet
Year: 2007
Tongue: English
Weight: 160 KB
Volume: 8
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(07)70244-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prospective, open, multi-centre phase I/

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction

✍ Markus Moehler, Ines Gockel, Hans-Peter Roessler, Dirk Arnold, Tanja Trarbach… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 212 KB

Assessing clinical benefit response in t

Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer

✍ Haruhiko Imamoto; Koji Oba; Junichi Sakamoto; Hiroyasu Iishi; Hiroyuki Narahara; 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 259 KB

Treatment of High-Risk Philadelphia Chro

Treatment of High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial

✍ Ribera, J.-M.; Oriol, A.; Morgades, M.; Montesinos, P.; Sarra, J.; Gonzalez-Camp 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 261 KB

385 A phase II trial to assess the effic

385 A phase II trial to assess the efficacy and safety of gefitinib (Iressa™) in patients with metastatic hormone refractory prostate cancer (HRPC) who progressed on treatment with a luteinising hormone releasing hormone analogue (or post orchiectomy) plus an antiandrogen

✍ G. Curigliano; O. De Cobelli; M.T. Sandri; L. Zorzino; C. Noberasco; T. De Pas; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 292 KB